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DEVELOPMENT OF TENOFOVIR PRODRUGS AS RECTAL MICROBICIDES FOR 
HIV PREVENTION 
Yafei Lyu, M.S. 
University of Pittsburgh, 2016 
 
Receptive anal intercourse is common among men who have sex with men (MSM), 
transgender women, and practiced by women around the world. The risk of becoming infected with HIV 
through receptive anal intercourse is 20 times greater than vaginal intercourse. Hence, there is an urgent 
need for the development of rectal specific topical pre-exposure prophylaxis (PrEP) products. In the 
current study, our lab developed enemas containing tenofovir (TFV) for rectal application, which may 
provide some advantages with respect to user acceptability and compliance. In addition to evaluation of 
TFV in enemas, prodrugs of TFV: tenofovir alafenamide fumarate (TAF) and hexadecyloxypropyl 
(HDP)-tenofovir (CMX157) were evaluated due to their increased potency and better safety profile. In 
this project, a high performance liquid chromatography (HPLC) method for TAF was developed and 
qualified. Preformulation studies for TAF including solubility, hydrolytic, thermal, photolytic, and 
oxidative stability and preservative compatibility were conducted. TAF was found to be susceptible to 
hydrolytic degradation in acidic pH (pH≤4) and degraded when exposed in an aqueous solution to 
temperatures greater than 25°C. TAF hypotonic and isotonic enema formulations (1.76 mg/mL) were 
developed and characterized with respect to pH, osmolality, and drug content. One-week stability of 
these enemas was assessed in 40°C/75% RH, 30°C/65% RH and 25°C/60% RH environmental 
chambers.  TAF enemas were stable for one week. In addition to the TAF enema, formulation efforts 
were initiated with CMX157.  A preliminary HPLC method for CMX157 was developed. Prototype 
CMX157 enemas were prepared and pH and osmolality testing conducted. Additional formulation 
v 
optimization is required to enhance TAF stability in an enema format.  Further investigation of the 
prototype CMX157 enema developed with respect to its physiochemical characteristics and stability is 
needed.  
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1.0  INTRODUCTION 
 HIV TRANSMISSION THROUGH ANAL INTERCOURSE (AI) 
Although significant strides have been made in the field of HIV treatment and prevention since its 
initial discovery in 1959, the prevention of new infections continues to be a great challenge [1]. 
Approximately 2.3 million new HIV infections occur annually, meaning that an average of 6,300 people 
are newly infected each day [1]. Some groups of people are at higher risk of infection than others, with 
men who have sex with men (MSM) bearing the greatest burden [2]. Although MSM represent only 4% 
of the male population in the United States, MSM accounted for 78% of new HIV infections among males 
and 63% of all new infections in the U.S. in 2010 [2]. Likewise, MSM accounted for 54% of all 
Americans living with HIV in 2011 [2]. This population is consistently most affected by HIV due to the 
18-fold increased risk of HIV transmission through anal intercourse (AI) in comparison to penile-vaginal 
intercourse. The risk of transmission is increased due to anatomical, physiological, immunological, and 
histological features of the colorectum [3]. As the practice of AI between both MSM and heterosexual 
couples has gained popularity, the need for the development of HIV preventative products has also risen. 
 SEXUAL COLORECTAL HIV-1 TRANSMISSION 
The knowledge of how HIV transmission occurs in the genital and rectal tract is essential for the 
development of an efficient and safe anti-HIV prevention strategy. Peripheral blood mononuclear cells 
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(PBMCs), which include lymphocytes (T cells, B cells, natural killer cells), monocytes, and dendritic 
cells (DCs), are all target cells of HIV viruses [4]. HIV gradually destroys the immune system by binding 
and killing CD4+ T-cells, which play a central role in cell-mediated immunity                                                                                                                                                                                                                                             
[5]. HIV uses the machinery of the CD4+ T-cells to multiply and spread throughout the body [5]. Entry of 
HIV into the host cell is contingent upon the binding of viral glycoprotein gp120 to the CD4 molecules on 
the host cell surface, which act as receptors [6]. Additionally, binding to chemokine co-receptors CCR5 or 
CXCR4 on the host cell surface is required by virus [6]. Several barriers must be overcome for HIV-1 
viruses to reach target cells in the genital and rectal tract [7]. Mucus is the first physical barrier that can 
prevent HIV-1 viruses from crossing mucosal epithelium [7]. Although stratified genital epithelial cells 
are not susceptible to HIV-1 infection and do not transcytose viral particles, these cells might be able to 
bind viral particles on their surface and thereby facilitate the infection of other cell types[7]. Although 
HIV can travel across the mucosal epithelial cell layers and enter the body on its own, damage to the 
epithelium can facilitate this process [8]. Damage to the epithelium often occurs through physical 
abrasion/trauma during sex, ulcerations, and inflammation [7]. Unlike the vaginal epithelium, which is 
composed of multiple layers, the rectal epithelium is only one cell thick and has large surface areas that 
provide easier access for HIV-1 to access underlying target cells [7]. Likewise, the neutral pH and 
minimum buffering capacity of rectal fluid provides little nonselective protection against pathogens 
including HIV[3]. Studies found that the gastrointestinal tract, including the rectum, is populated with 
HIV target cells such DCs and lymphocytes [9]. In addition, the rectum itself contains abundant microfold 
cells that are known to initiate mucosal immunity and allow for transport of microbes and particles across 
the epithelial cell layer from the gut lumen to the lamina propria, where interactions with immune cells 
can take place [7]. These physiological differences contribute to increased risk of HIV infection through 
anal intercourse compared to vaginal intercourse [10]. After the HIV virus transfers across the epithelial 
barrier into the underlying stromal tissues, which are populated with HIV target cells, HIV-localized 
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mucosal infection is established [7]. HIV viruses can further migrate to draining lymph nodes by 
migratory dendritic cells, resulting in systemic infection [7].  
 
 PREVENTION OF HIV-1 SEXUAL TRANSMISSION--PRE-EXPOSURE 
PROPHYLAXIS (PREP) 
1.3.1 The Concept of PrEP 
PrEP refers to daily medication taken by people at very high risk for HIV infection to lower 
their chances of infection [11]. To date, dosage forms expolored for administration of PrEP agents 
includes those involving the oral, injectable, or topical route of delivery. The Food and Drug 
Administration (FDA) has approved the oral product, Truvada® (Gilead Sciences, Inc., Foster city, CA), 
for PrEP.  Truvada® consists of antiretroviral drugs emtricitabine (FTC) and tenofovir disoproxil 
fumarate (TDF).  An injectable form of PrEP, featuring a two-drug formulation of cabotegravir and 
rilpivirine, is currently in Phase III clinical trials, while a one drug formulation of cabotegravir has 
shown promise in HIV prevention among adult males in a Phase II clinical trial [12, 13]. In this thesis 
work, we focused on topical PrEP, which is also referred to as a “microbicide”. Condom use is a well-
known and effective strategy for prevention of sexually transmitted diseases (STDs) including 
HIV/AIDs. However, only 70% effectiveness was achieved with reported consistent use during penile 
AI among MSM as opposed to 80% among heterosexuals [14]. Studies also revealed that, out of the 
one-third of US heterosexuals who have engaged in AI, the majority reported that they do not use 
condoms during AI [15]. The Centers for Disease Control and Prevention (CDC) provided estimates of 
effectiveness for various strategies to prevent HIV transmission in 2015. They reported that Truvada 
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offered 92% and 90% effectiveness among MSM and heterosexuals, respectively [16]. So far, six 
clinical trials have demonstrated the tight relationship between PrEP HIV prevention effectiveness and 
patient adherence [17]. In other words, effectiveness declines if patients don’t take or use PrEP 
medications regularly [18]. PrEP must be used consistently in order to achieve desired therapeutic 
effects.  
1.3.2 Microbicides 
HIV microbicides are prophylactic biomedical products that are self-administered to the rectum 
or vagina [19]. Microbicides have been developed in a variety of dosage forms, including tablets, gels, 
creams, films, rings. HIV microbicides are used to prevent the sexual transmission of HIV and give the 
user control due to the self-dosage [20]. The concept of microbicides was initially based on offering 
women protection under their own control [21]. Early development of microbicides focused on products 
that incorporated non-antiretroviral (non-ARV) medicines that have no specific mechanism of action [20]. 
These products can also work by inactivating pathogens, strengthening the body’s natural defenses, or 
blocking viruses from getting into healthy cells [20]. For example, an early microbicide composed of 
polyanionic compounds prevented viral attachment to target cells by electrostatic interaction [20]. In 
addition to secreting medications, microbicide creams and gels also provide lubrication to physical 
barriers, which can decrease trauma to the mucosal epithelium and thus reduce the risk of HIV 
transmission [7, 20, 22]. Recently, the development of microbicides has been focused on microbicides 
containing highly potent and HIV-specific antiretrovirals (ARVs) that can be incorporated into distinctive 
dosage forms [20]. The CDC reported a 96% reduction in HIV transmission between HIV-positive men 
and women using antiretroviral therapy and their HIV-negative partners [16]. Therefore, incorporation of 
ARVs into microbicides is a promising endeavor.  
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 TENOFOVIR (TFV) AND ITS PRODRUGS 
1.4.1 Classification of Anti-HIV Medications 
The life cycle of HIV virus offers several specific targets for ARVs. There are several classes of 
ARV microbicides that are currently under development. Two of these are entry inhibitors and reverse-
transcriptase inhibitors [20]. Entry inhibitors can function in several ways.  Some impede the binding of 
the HIV virus to CD4 receptors and CCR5/ CXCR4 coreceptors, thus blocking entry into target cells [7]. 
Others in this class of ARVs interact with gp120 on the HIV virus. In this project, we focus mainly on 
nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), which allosterically and irreversibly bind 
to reverse transcriptase and thereby prevent HIV replication [23]. Reverse transcriptase (RT) is a viral 
enzyme used to convert viral mRNA into double-stranded viral DNA, which can then be integrated in the 
host cell chromosome, allowing host replication of the virus [24]. Therefore, RT is crucial and necessary 
for HIV replication and spread [24]. 
 NRTIs have been shown to be highly potent in blocking the action of RT. Therefore; this class of 
ARVs is relevant to microbicide development, as they can maintain sufficient anti-HIV activity 
throughout the interval between application to the vagina or rectum and the deposition of semen [7, 23]. 
Among this class, TFV is an acyclic nucleotide that rapidly converts to its active form, TFV-diphosphate 
(TFV-DP), from TFV monophosphate within cells [25-27]. The active form has a long terminal half-life 
of up to 17 hours, as it is not subject to intracellular deamination and deglycosylation [26]. TFV has 
already been approved by the FDA as an oral tablet called Viread® (Gilead Sciences, Inc., Foster city, 
CA). This tablet incorporates the prodrug version of TFV--TDF, which has higher bioavailability 
compared to TFV in the treatment of HIV infection and chronic hepatitis B virus infections. TDF is a 
fumaric acid salt of the bis-isopropoxycarbonyloxymethyl ester of TFV [26]. TDF is readily absorbed by 
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the gastrointestinal epithelial cells with an oral bioavailability of 25% [26]. Degradation of TDF to its 
monoester and subsequently to TFV occurs readily in the intestinal mucosa by the action of 
carboxylesterases and phosphodiesterases, respectively, following oral administration [26]. 
1.4.2 Vaginally and Rectally Applied TFV Gel 
TFV-incorporated microbicides are being developed in many dosage forms, including rings, gels 
and films for prevention of HIV acquisition through vaginal intercourse. Only the vaginal gel dosage form 
has been reformulated for safe use in the rectal compartment. CAPRISA 004 provides the first proof of 
concept study that 1% TFV gel can reduce women’s risk of HIV via vaginal sex [28]. This clinical study 
which focused on evaluating the effectiveness and safety of 1% TFV gel vaginally, showed an estimate of 
39% reduction in HIV infection among 444 sexually active, HIV-uninfected 18- to 40-year-old women in 
South Africa [23]. This study also reported that HIV incidence was 54% lower among high adherers in the 
TFV gel arm than the placebo gel arm [23]. Another clinical study assessed the safety and tolerability 
demonstrated by 1% TFV gel used vaginally twice daily and found the gel to be well tolerated, with only 
mild adverse events observed in the majority of women users [22]. However, this promising TFV vaginal 
gel cannot be used for rectal application due to its hyperosmolality, which can result in damage to the 
rectal epithelium [29]. Therefore, further investigation was put into development of a TFV gel that could 
be rectally applied [3, 29].  
Hyperosmolality not only provides HIV with more direct access to CD4 target cells by breaking 
down the epithelium, but it also causes colonic inflammation due to enhanced luminal permeability [29, 
30]. This may lead to poor acceptability among users. A Phase I clinical study (MTN-006) investigating 
safety and acceptability of vaginal TFV gel when applied rectally reported poor acceptability and some 
safety concerns [31]. A reduced glycerin TFV gel (RG-TFV gel) with similar overall characteristics 
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except for osmolality and spreadability/firmness was formulated. In the MTN-007 study this RG-TFV gel 
showed a 73% lower osmolality, a 29.6% increase in spreadability, and a 27% decrease in firmness 
compared with vaginal TFV gel [29]. For polarized colorectal and ectocervical tissue, the colorectal and 
ectocervical epithelium was intact after exposure to RG-TFV gel, in contrast to fractured or sloughed off 
epithelium after exposure to the vaginal TFV gel [29]. Efficacy testing conducted on tissue explants 
showed a 3log10 decrease and a ≥1.5 log10 decrease in HIV-1 p24 release after dosing with TFV gel in 
colorectal and ectocervical explants, respectively [29]. This suggests that the RG-TFV gel doesn’t 
compromise the effectiveness against HIV infection compared with vaginal TFV gel [29]. In summary, 
RG-TFV gel, possessing near physiological osmolality, showed improved epithelial integrity and 
maintained anti-HIV activity equal to vaginal TFV gel [29]. The acidic pH of this formulation remains a 
potential issue for RG-TFV gel rectal application as it may cause some discomfort associated with 
adherence, although it is unclear whether frequent rectal use of acidic pH products will impact the 
gastrointestinal tract in terms of epithelial integrity [29]. This pre-clinical investigation of RG-TFV gel 
suggests that an isotonic osmolality and a pH value suitable to local environment may be preferable in 
terms of rectal microbicide product development [29].  
Subsequently, TFV rectal specific gel and liquid products were formulated with a neutral pH and 
slightly above isoosmolality [32]. These formulations retained resected normal human colonic tissue 
viability and maintained tissue architecture after exposure to HIV-1 [32]. It was also suggested that since 
it was intended that the liquid products would be ‘‘enema-like’’ and deliver drug further into the rectal 
compartment, this kind of product would easily spread over the mucosal surface which could provide 
more protection than viscous gels that require shear forces to spread [32].  
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 TFV PRODRUGS 
1.5.1 Designing Aim of TFV Prodrugs 
As introduced previously, some microbicides being developed incorporate anti-HIV 
pharmaceutical agents that were originally introduced for the treatment of HIV. TFV has high potency 
both in vitro and in vivo due to its long intracellular half-life [33]. However, as TFV is a di-anion at 
physiological pH, it has poor cellular permeability, thus decreasing its bioavailability [33]. Additionally, 
TFV, which contains a phosphonate moiety, is the substrate of organic anion transporter and rapidly 
eliminated through proximal tubule cells by efflux transporters such as multidrug resistance-associated 
proteins [33]. This elimination results in accumulation of TFV in proximal tubule cells due to drug-drug 
interaction thereby causing renal toxicity [33, 34]. 
 TDF, synthesized as an oral prodrug of TFV, exhibits five-fold higher intracellular levels of TFV 
after oral administration compared with equivalent TFV injected subcutaneously [33]. This greater 
intracellular concentration achieved by TDF resulted in a three-fold decrease of HIV viral load in a 
human clinical trial [33]. However, TDF was designed to release TFV in plasma and has been shown to 
metabolize 170-fold faster in plasma than in target cells, resulting in a nephrotoxicity issue [33]. 
Therefore, new classes of ARVs that can circulate systemically as prodrugs and undergo rapid conversion 
to TFV intracellularly have attracted attention [33]. 
1.5.2 Tenofovir Alafenamide Fumarate (TAF) 
Tenofovir alafenamide fumarate (GS-7340 or TAF) is one of the stereoisomers synthesized from 
(R)-PMPA (TFV) and (L)-isopropyl alanine ester [33]. Preclinical studies have demonstrated a 200-fold 
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increase in plasma stability (circulating as prodrug) and a 400-fold increase in accumulation of TFV and 
its active form (TFV-DP) in lymphatic tissues and PBMCs compared to TDF [26]. TAF has showed a 
1000-fold increase in potency in vitro over TFV and has shown antiretroviral activity against both wild 
type and drug-resistant HIV-1 strains with excellent in vivo pharmacokinetic properties [26, 27]. The 
preferential distribution into PBMCs and other lymphatic tissues are hypothesized to be attributed to the 
increased metabolic activity of these tissues [33]. In addition, by masking the phosphonate group present 
in the TFV structure, TAF is more hydrophobic than TFV. Therefore, TAF can achieve more cellular 
uptake as compared to TFV. However, the detailed mechanism for the selective intracellular targeting of 
TAF is not fully understood [33]. Following rapid target cell uptake, TAF is hydrolyzed at the carboxyl 
ester bond in lysosomes by the cathepsin A, the serine and cysteine proteases [26]. Then, the unstable 
product formed during the first-step hydrolysis spontaneously releases phenol by intramolecular 
cyclization and hydrolysis to a negatively charged, cell impermeable TFV-alanine intermediate. This 
intermediate is metabolized to parent TFV followed by downstream phosphorylation to TFV-DP [26]. A 
Phase II clinical study comparing darunavir/cobicistat/emtricitabine/TAF (D/C/F/TAF) and 
darunavir/cobicistat/emtricitabine/TDF (D/C/F/TDF), all ARVs in HIV-infected treatment-naïve adults, 
showed orally administered D/C/F/TAF resulted in a 6.5-fold higher TFV-DP exposure in PBMCs with 
91% reduced TFV exposure (AUCtau) in plasma than D/C/F/TDF [35]. Patients dosed with D/C/F/TAF 
showed a smaller increase in serum creatinine, significantly less renal tubular proteinuria, and less change 
in BMD at both hip and spine compared to patients treated with D/C/E/TDF [35]. All of these studies 
demonstrate that TAF has improved the bone and renal profile and has increased antiviral activity 
compared with TDF. Another clinical study comparing TDF 300mg with TAF 50mg and 150mg, 
respectively, showed TAF at both doses had a significant decrease in HIV-1 RNA [36]. Viral loads were 
reduced -1.71-log and -1.57-log for 150 mg and 50 mg doses, respectively, compared to 0.94-log for TDF 
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at day 14 [26]. Phase III studies evaluating D/C/F/TAF versus D/C/F/TDF in treatment-naive adults are 
ongoing.  
1.5.3 Hexadecyloxypropyl-Tenofovir (CMX157) 
CMX157, a hexadecyloxypropyl (HDP) prodrug, is a lipid conjugation to TFV that mimics the 
natural lipid uptake pathway. Similar to TAF, it is not cleaved in the plasma by nonspecific esterase. As it 
is not a substrate of human organic anion transporters correlated to TFV-induced nephrotoxicity, it has 
decreased renal excretion and increased intracellular drug exposure compared to TDF and Tenofovir [26, 
37]. Free TFV is released intracellularly by hydrolysis to remove HDP lipid by phospholipases [26]. 
There is also a hypothesized mechanism that CMX157 may hitchhike on the HIV virus by inserting its 
lipid conjugate into the viral envelope, thus achieving an enhanced intracellular delivery. In vitro studies 
reported that CMX157 is >200-fold more potent than TFV against wild type as well as all major HIV 
subtypes resistant to current therapies [26]. The amount of TFV and its active form after exposure to 
CMX157 that accumulated in human PBMCs was shown to be much higher than those accumulated after 
exposure to TFV [38]. CMX157 has no apparent toxicity when given orally to rats for 7 days at doses of 
10, 30, or 100 mg/kg/day [34]. A Phase I clinical study comparing healthy volunteers receiving a single 
25mg-400mg dose of CMX157 to healthy volunteers receiving a standard dose of Viread® reported that 
CMX157 was well tolerated and caused no adverse event trends [37]. TFV -DP was measurable in 
PBMCs from all patients following a single 400 mg dose of CMX157 [37]. In fact, a once-weekly dosing 
regimen of CMX157 was recommended after PBMC levels of TFV--DP remained detectable for six days 
after the  ingle 400mg dose [37]. 
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Figure 1 Chemical structures of (A) TFV; (B) TAF and (C) CMX157 
Picture by ChemDraw® 
 ENEMAS 
1.6.1 Highly Acceptable HIV Prevention Strategy among MSM 
Enemas, also referred to as rectal douches (Figure 2), are liquid treatments, which is a insertion of 
fluid into the anus, for medical or hygienic reasons [39]. The main purpose of most commonly used 
enemas is to help relieve severe constipation or for bowel cleansing, as in the Fleet® enema (Fleet 
laboratories, Lynchburg, VA) [40]. However, depending on the dissolved active agents, enemas can also 
Phosphate 
group
HDP moiety
A B
C
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be used to treat diseased rectum, sigmoid, and descending colon [41]. Indications for these enemas 
include Crohn's disease and ulcerative colitis, which can be treated using a betnesol retention enema [41]. 
Enemas, depending on their indication, have constituents like saline or phosphate buffer, and some may 
contain active pharmaceutical ingredients (APIs). Enemas are delivered using a device that can utilize 
either a nozzle design or spray pattern [42].  
Enemas are widely used and highly acceptable among MSM. According to an international 
survey, among 1339 respondents representing 112 countries, 66% reported they have used rectal 
douching, among whom, 83% reported high frequency of use before anal intercourse [43]. A study 
enrolling 105 MSM (78 HIV-negative, 27 HIV-positive) who had unprotected receptive anal intercourse 
(URAI) in the previous year, 53% of HIV-negative and 96% of HIV-positive men douched in preparation 
for sex [44]. This popularity of douching before sex among MSM makes it a potential high-compliance 
dosage form. It should be noted that enemas may cause trauma to the rectum which can increase the risk 
for HIV and other STD’s. There are some behavior studies investigating why men who are engaged in AI 
douch before or after sex. Studies attributed this behavior preference to the desire for cleanliness prior to 
sex.   
With respect to applying enemas as rectal microbicides, these products if formulated 
appropriately may decrease the shear during intercourse, possibly providing protection against micro-
trauma during intercourse, which provides the HIV virus easier access into the body [3]. Additionally, the 
large percentage of water in enemas may enhance drug coverage of a sufficient surface area of the 
colorectum, which could provide potential advantages against HIV transmission, considering the natural 
poor wetting conditions of the colorectum [3]. However, currently marketed lubricant or rectal douches 
are hyperosmolar, a trait that may compromise the integrity of colorectal epithelium, leading to increased 
risk of HIV transmission [45]. Therefore, a safe rectal douche with anti-HIV effects is in urgent need.  
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Figure 2 Representative image of typical tenofovir enema 
1.6.2 Rationale of a Safe Rectal Enema Design 
A successful, rational design for a rectal microbicide relies on the understanding of HIV 
transmission pathology (distribution and clearance) in the colorectum.  In a study conducted on adult 
males with a history of receptive AI, SPECT/CT imaging showed that cell-free HIV distribution can reach 
the rectosigmoid colon (Figure 3) and the maximum distribution occurred between 4 and 24 hours [46]. In 
order to cover all possible temporal distributions of HIV seen in their study, they suggested a microbicide 
product should be able to distribute into the sigmoid colon and be sustained for a minimum of 24 
hours[46].  Findings by the Hendrix group from Johns Hopkins University concluded that a microbicide 
should cover all the colonic locations during the periods of HIV exposure in order to achieve better 
efficacy [47]. As discussed previously, the hyperosmolality of enemas has been reported to cause 
epithelial damage, which can potentially exacerbate HIV transmission [48]. In the absence of an 
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accessible rectal microbicide, many users tend to use tap water, which is extremely hyposmolar and has 
been reported to cause epithelial loss [48]. It is crucial to define the osmolality range with a desired 
distribution profile for rectal application of microbicide enemas. A study conducted by the Hendrix group 
assessing the distribution, safety, and acceptability of isoosmolar enemas (NormosolTM-R, 295mosm/kg) 
as opposed to hyperosmolar enemas (Fleet®) and tap water showed that isoosmolar enemas had a better 
proximal colonic distribution (up to splenic flexure). Additionally, this study found that hyperosmolar 
enemas exhibited sloughing of colon epithelium, as predicted [48]. Hyposmolar enemas exhibited an 
intermediate distribution between these isoosmolar and hyperosmolar enemas. The pH and buffering 
capacity in the colorectum are two important parameters that should be taken into consideration when 
developing rectal microbicides. Extreme pH values may lead to irritation and discomfort, both of which 
potentially impact user adherence and cause adverse effects [3]. It is advisable to develop a rectal 
microbicide with a pH range of 7-8, although the effects of pH change to the normal rectal fluid pH on 
epithelium integrity and HIV transmission is unclear [32].  
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Figure 3 Cartoon of colon anatomy 
 
Previous studies have revealed that by use of an osmotic gradient for fluid absorption and 
secretion, vaginal drug delivery could be improved to reach the entire epithelial surface, including the 
deep folds penetrating through the mucus layer [49]. Likewise, an osmotic gradient should be employed 
in enema development to achieve similar delivery. A study conducted by Johns Hopkins University in the 
mouse model found that a sodium-based, moderately hypotonic enema containing TFV was able to 
achieve high local tissue levels of the drug with minimal systemic exposure while providing enhanced 
local drug retention[50]. It was also found that colorectal tissue coverage was enhanced by hypotonic, 
absorption-inducing enemas (0.9% saline and deionized water) and bulk fluid absorption only occurred 
when Na+ was present [50]. This conclusion was based on the physiology of colorectum, since sodium 
Anus
Sigmoid colon
Rectum
Descending
colon
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ion absorption ubiquitous across the human colon and is directly related to water. Water absorption is 
passive in the colon and is promoted by the osmotic pressure produced by sodium chloride absorption 
[51].Sodium and chloride absorption can occur without water absorption, due to passive diffusion [52]. 
Sodium ions passively diffuse along the favorable electrochemical gradient on the apical side of 
colonocytes and are actively transported on the basolateral membrane of colonocytes [51]. It has also 
been demonstrated by this study that moderately hypotonic simulated colon solution (SCS, 150msm/kg) 
and near isotonic tris buffered saline (TBS, 450mOsm/kg) didn’t have any detected systemic drug 
absorption 30mins after administration [50]. But SCS provided optimal tissue drug levels compared with 
tap water, Fleet® enema and near isotonic TBS [50]. These findings suggest that hypotonic enemas induce 
water absorption, which may transport drug by bulk fluid flow to epithelial tissue, while remaining mild 
enough to reach systemic circulation [50]. In terms of epithelial toxicity, tap water and SCS did not 
induce any detected epithelial damage [50]. Another study assessing the distribution, toxicity, and 
acceptability of three different types of enema of varying osmolarity in healthy MSM showed that 
NormosolTM-R, an isotonic solution of balanced electrolytes in water for injection, has the greatest 
luminal and tissue concentrations of radiolabeled enemas with plasma concentrations (AUC and Cmax) 
lower than distilled water enemas and increased proximal colon distribution (up to splenic flexure) [48]. 
NormosolTM-R also exhibited the highest degree of dose retention compared to fluid-absorption inducing 
solutions in terms of both luminal and tissue concentrations [48]. As SCS was not used in the study, it is 
hard to determine whether SCS has a more favorable profile in terms of local and systemic drug 
concentrations and dose retention as compared to NormosalTM-R.  
In summary, it is suggested that slightly hypotonic enemas containing sodium ions are able to 
achieve the optimal luminal & colonic tissue drug distribution and local tissue drug level with minimal 
systemic drug exposure. 
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Figure 4 Water and sodium ions absorption in rectum 
 
 SCOPE OF WORK 
Rectal enema products containing TFV and its prodrugs may be a promising means to prevent 
HIV sexual transmission. In the NIAID funded Development of a Rectal Enema as Microbicide 
(DREAM) Program (Grant # U19AI113127), it is hypothesized that a moderately hypotonic enema 
incorporating prodrugs of TFV could achieve sufficient distribution and amount of the API in colorectal 
tissue, with minimal systemic drug exposure.  To this end, TFV enema products were developed in our 
lab.  For this TFV enema product, a dose of 220mg/125mL was selected to achieve the same colon tissue 
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CD4+ cells TFV-DP concentration as a TFV 1% rectal gel dose. Utilization of this dosing level allows for 
comparison of the 1% TFV gel to the TFV enema formulation. TFV enemas were formulated with 
isotonic and hypotonic osmolality for comparison of the effect of osmolality on TFV-DP tissue 
concentration in animal studies. The TFV enemas developed were shown to be stable for over one year.  
This TFV enema formulation served as the basis for formulation of TFV prodrug enemas described in this 
thesis. 
Specifically, this thesis work focused on developing analytical tools for the analysis of TAF and 
CMX157, pre-formulation work on stability of TAF under varying conditions, and formulation work to 
incorporate TAF and CMX157 into buffers within target pH and osmolality.  Since little information is 
available in the literature regarding the physiochemical characteristics of TFV prodrugs, TAF and 
CMX157, we designed a series of preformulation studies to explore their physiochemical characteristics. 
 SPECIFIC AIMS 
There are three aims in this thesis project.  
Specific Aim 1:  Identify degradation pathways for TAF by performing preformation studies under 
selected conditions  
Specific Aim 2:  Formulation development of TAF enemas and characterizations of pH, osmolality and 
drug content 
Specific Aim 3:  Formulation development of CMX157 enemas and characterizations of pH, osmolality 
and drug content 
 19  
2.0  DESIGNING TAF ENEMAS FOR HIV PREVENTION 
 
 THE RATIONALE OF CONDUCTING PREFORMULATION STUDIES 
 
Solubility, the dissolution of solute in solvent to yield a homogenous system, is an important 
parameter used to achieve the desired concentration of drug for the anticipated pharmacological response 
[53]. For any drug to be absorbed, the drug must be in solution at the site of absorption [53]. 
Determination of drug candidate solubility typically occurs during the preformulation stage of 
pharmaceutical product development. Solubility is also very important in drug discovery and formulation 
development phases [54]. There are two commonly used terms for solubility: kinetic solubility and 
intrinsic solubility [54]. Kinetic solubility is the concentration of a compound at the time when an induced 
precipitate first appears in the solution. It is often investigated in the early phase of drug discovery [54]. 
On the other hand, intrinsic solubility refers to the maximum quantity of the substance that can be 
completely dissolved at a given temperature and pressure in a given amount of solvent. This measure is 
thermodynamically valid as long as a solid phase is in equilibrium with the solution phase [55]. In terms 
of drug development, the intrinsic solubility is considered more important [54]. To note, the term intrinsic 
solubility is used to describe the solubility of the un-ionized form in the absence of acid or alkali as pH 
affects solubility of ionizable compound. Intrinsic solubility is the concentration of a compound in a 
saturated solution when excess solid is present, and solution and solid are at equilibrium [56]. 
 There are many methods to determine intrinsic solubility, but the saturation shake-flask method 
is considered to be the classical method. This method uses a sample that is typically prepared by adding 
an excess amount of solid to the solubility medium to produce a suspension [57]. With an agitation rate 
adequate to prevent particle agglomeration and to ensure particle contact with the diluent, samples often 
reach equilibrium quickly (within 24 h) [57]. It is generally accepted that equilibrium has been reached 
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when multiple samples, assayed after different equilibration time periods, yield the same result for 
apparent solubility [57]. Currently, there is no standardized way to conduct the shake flask method for 
determining solubility [54]; therefore, one may find varied stirring and sedimentation times and 
techniques for collecting aliquots in published papers [58]. These factors all account for the variability 
among solubility determinations. This may explain why reported solubility of a drug molecule can vary 
amongst different developers. Besides this, solubility determination among various compounds is affected 
by other factors including particle size, crystallinity, and molecular features [58]. In our solubility studies, 
we utilized 1h sonication and room temperature rotation to reach equilibrium up until 24h. This method 
was applied to promote saturation of TAF in the solubility medium. In addition to procedural effects on 
the determination of solubility, intrinsic factors must be taken into account when conducting a thorough 
solubility study. The effects of pH and ionic strength on the solubility of ionizable compounds are 
extensively examined phenomenon [54]. As TAF is ionizable, solubility experiments with consideration 
of pH and ionic strength of the solubilizing medium were conducted. 
Chemical stability of pharmaceutical agents is highly important for developing a successful 
formulation, determining appropriate packaging, and indicating proper storage conditions and shelf-
life[58]. U.S. Food and Drug Administration (FDA) and the International Council for Harmonisation 
(ICH) require stability test data, which indicate the quality of the product and stability over time under 
various environmental factors. Stability testing can be divided into two main parts: forced degradation 
studies (stress testing) and accelerated degradation studies [58]. Forced degradation studies of novel drug 
substances products are essential to help develop and demonstrate the specificity and sensitivity of the 
analytical tools [59]. In addition to demonstrating specificity, forced degradation studies can be used to 
determine the degradation pathways and products of the active pharmaceutical ingredients (APIs) that 
could form during storage, and facilitate formulation development, manufacturing, and packaging [59]. 
For forced degradation studies, conditions beyond temperature, including photolysis, low and high pH, 
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and oxidation are typically examined. For accelerated conditions, temperature is the most common factor 
because its relationship with the degradation rate is defined by the Arrhenius equation [60]. In accelerated 
stability tests, a product is stored at elevated stress conditions [60]. The real-time stability, during which a 
product is stored at the recommended storage conditions and monitored can be predicted using known 
relationships between the acceleration factor and the degradation rate [60]. However, the guidelines on 
conducting preformulation studies, and what conditions to test, are not strictly defined due to variation 
between drug products [58]. Therefore, designing preformulation studies that seek to determine intrinsic 
stability must be based on the API’s chemical structure and anticipated molecular behaviors.  
As stability data should be able to indicate possible degradation during manufacturing and under 
storage conditions, chosen stress conditions must be indicative of the degradation mechanism of action 
under real conditions [58]. Some stressed conditions are considered necessary for an overall pre-
formulation study: acid and base hydrolysis, thermal degradation, photolysis, and oxidation. Additionally, 
freeze–thaw and shear are often tested [58]. Selected conditions should force degradation of the drug 
substance between 5% to 20% in order to validate a stability indicating method [58]. However, a forced 
degradation study does not have to induce a degradation product [58]. Stability testing can be done over a 
short period of time under harsh conditions or labile conditions [58]. Optimization of stress conditions is 
required, as anticipated conditions may not degrade the drug experimentally [58]. 
The preservatives sodium methylparaben and sodium propylparaben were used in TAF enema 
formulation to inhibit bacterial growth. These two preservatives are commonly used in rectal enema, 
liquid, solution or suspension formulations and have adequate solubility in water [61]. The sodium 
methylparaben and sodium propylparaben preservative concentrations in TAF enemas were at 0.18% and 
0.02% respectively in accordance to the guideline and our previous experience with these preservatives 
[61].  
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 MATERIALS & METHODS 
 
2.2.1 High Performance Liquid Chromatography (HPLC) Method Development  
 
The HPLC method was developed according to an assay used to analyze metabolites of TAF[62].  
TAF was analyzed on a ZORBAX Agilent (Agilent Technologies, Santa Clara, CA) XDB-C18 column 
(3.5 μm, 100 ×4.6 mm) using the Waters (Milford, MA) HPLC system connected to a diode array detector 
(Waters 2996 photodiode Array). An isocratic elution was utilized by mobile phase A (5% Acetonitrile in 
25mM phosphate buffer and 5mM t-butyl ammonium bromide, pH=6) and B (60% Acetonitrile in 25mM 
phosphate buffer and 5mM t-butyl ammonium bromide, pH=6) for 8 min at a flow rate of 2mL/min at 
ambient temperature in auto-sampler. The UV detector has a PDA setting of 210nm~400nm at 1.2nm. 
TAF was detectable at the wavelength of 260nm. Sample injection volume was 10μL. TAF was identified 
by comparison with TFV retention time (tR=3.7min). The method was then validated by examining 
precision, accuracy, linearity, and challenged at various pH and oxidative conditions. The precision was 
performed by testing samples of three concentrations, with 10 injections for each concentration on each 
day for three days. Samples were diluted by 25% acetonitrile before analysis within validated linearity 
range and then analyzed on HPLC.  
2.2.2  Preparations of Solubility Medium and Buffers 
Standard buffer solutions with pH values of 2, 4, 5, 6, 7, and 8 were prepared according to United 
States Pharmacopeia (USP 26). For the pH-dependent solubility profile, USP citrate and phosphate 
buffers ranging from pH 4-8 were utilized. The ionic strength-solubility profile was assessed using serial 
dilutions of purchased 10X PBS (MediaTek, Inc., Hsinchu, Taiwan) ranging from 0.5X—5X PBS. TAF 
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solubility was tested in varying pH buffers, PBS, water and normal saline. TAF was well suspended in 
media and rotated for 24h. After rotation, suspension was centrifuged and filtered through a 0.22μm filter. 
Aliquots was diluted within validation range of the validated HPLC method and assayed on HPLC.  
2.2.3 Preparations of TAF Stock Solution  
TAF was dissolved in 100% acetonitrile at a concentration of 7mg/mL  
 
2.2.4 Hydrolytic Studies 
 
Hydrolytic studies were conducted in 0.1M hydrochloric acid (HCl, pH=1) and 0.1M sodium 
hydroxide NaOH, pH=11) USP buffers. The pH of each buffer was measured using an accumet XL600 
dual channel pH meter (Fisher Scientific, Pittsburgh, PA), before and after addition of TAF stock solution. 
Diluents from stock solution were prepared. Samples were stored at room temperature until 24h. 100μL 
aliquots of each sample were collected and analyzed for drug content at predetermined time points: 0h, 
2h, 4h, 6h, 8h, and 24h. Acid and base controls without API were assayed by HPLC at each time point to 
ensure that change in acid or base would not affect potential TAF degradation. An API control was also 
performed and assayed at each time point.  
2.2.5 Oxidative, Thermal and Photolytic Studies 
The same stock solution and dilution procedure was used for oxidative, thermal, and photolytic 
studies. For oxidative studies, 3% and 0.03% hydrogen peroxide (H2O2) was diluted from 30% H2O2 
(Fisher Scientific, Pittsburgh, PA) and 3% H2O2 (Target, Minneapolis, MN) respectively with water. TAF 
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diluents in 3% H2O2 were assayed at predetermined time points: 0h, 2h, 4h, 6h and 24h. At 0.03% H2O2, 
100μL aliquots were taken and assayed at predetermined time points: 0h, 2h, 4h, 6h, 24h, and 72h.  
For thermal studies, TAF stock solution prepared was diluted in water and diluents were placed in 
40°C and 60°C water baths, 100μL aliquots were taken on predetermined time points: 0h, 2h, 4h, 6h, 8h, 
24h, 72h and assayed immediately on HPLC.  
For photolytic studies, TAF was dissolved directly in water and well sealed in 2ml plastic vials; 
All the samples were stored in a 25°C/60% relative humidity environmental chamber (Caron 6010, Caron 
Products & Services, Inc.). Aliquots were taken on time zero and 72h.  
2.2.6 TAF Enema Preparations 
Isotonic and hypotonic 1.76mg/ml TAF enemas were prepared according to the formulas (Table 
1), 100mL purified water was weighed into a 250mL beaker, and stirred for 5mins, followed by the 
addition of sodium chloride, sodium parabens, and TAF. The solution was then sonicated until all 
components were dissolved. After sonication, 5% hydrochloric acid (HCl) diluted (Fisher Scientific, 
Pittsburgh, PA) was added to the solution, with pH measurement. The osmolarity and drug content were 
then measured immediately after preparation. The prepared TAF enema was separated and placed in three 
different environmental chambers (Caron 6010, Caron Products & Services, Inc.): 25°C ± 2°C/60% ± 5% 
RH, intermediate 30°C ± 2°C/65% ± 5% RH, and accelerated 40°C ± 2°C/75% ± 5% RH, as described 
previously. Aliquots were taken to measure for pH, osmolality, and drug content at day 0, day1, day2, 
day3, day5 and day7. The instruments used for osmolarity were a Model 3320 osmometer (Advanced 
Instruments, Inc., Norwood, MA).  
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Table 1 Formulations of TAF isotonic and hypotonic enemas 
Component 
Hypotonic TAF 
enema Amount 
Per Batch 
Isotonic TAF 
enema Amount 
Per Batch 
 
Function 
TAF 176mg 176mg API 
Sodium 
Methylparaben 
0.18g 0.18g 
Preservative 
Sodium 
Propylparaben 
0.02g 0.02g 
Preservative 
NaCl, USP 0.370g 0.793g Osmogen 
5% HCl 
610µL 610µL 
 
pH modifier Diluted from 
37% HCl 
Purified Water 100mL or 100g 100mL or 100g Solvent 
2.2.7 Preservative Compatibility 
Three independent, isotonic TAF enemas (1.76mg/ml) were prepared with no addition of 
preservatives. Aliquots were taken to measure pH and drug content. Following this, the preservatives 
were added and assayed. Monitoring drug content results assessed the stability of TAF as an indicator of 
compatibility. 
2.2.8 Statistical Analysis 
All results are presented as the mean ± standard deviation (SD). Pairwise or unpairwise 
differences were determined by Student’s t test. One-way ANOVA with Bonferroni post-hoc test was 
conducted comparing more than two groups. A p value <0.05 was considered statistically significant. In 
some of the forced degradation studies and stability studies, drug concentration determined over time is 
reported as TAF percent recovery (% of time zero) ± SD. 
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 RESULTS 
 
2.3.1 HPLC Method 
 
As part of the preformulation studies, an HPLC analytical method was developed and validated. 
The retention time of TAF was observed at 3.73±0.08 minutes. The limit of detection (LOD) was 
estimated to be 0.17 μg/mL, and the limit of quantification (LOQ) was 0.5μg/mL based on signal-to-
noise. A linear standard curve was obtained over a range of 0.5-150μg/Ml. No TAF degradants were 
detected during the analysis. The perfect overlay among the 10 TAF chromatograms affirms the 
repeatability of samples at the lowest quality control (QC) level (4ug/mL) (Figure 5). This developed 
HPLC method was applied to quantify solubility of TAF in different solvents and drug concentrations in 
samples collected throughout the stability studies. The regression coefficients of all calibration curves 
were greater than 0.999 in three days. The coefficient of variation (CV), reported as relative standard 
deviation (RSD), is as below (Table 2): 
 
 Table 2 Precision results of TAF validation for three days 
 
 
 
 
RSD 
(%) 
Low  
Conc. 
Middle 
 Conc. 
High  
Conc. 
Precision 3.82% 4.23% 3.66% 
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Figure 5 Overlay of the HPLC chromatograms showing repeatability at the low QC level of TAF 
(4ug/ml).  
10 injections of each QC level were made on each day of three days. RSD was 0.981% for injections 
shown above. TAF peaks were consistent on each day.  
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2.3.2 Solubility 
Saline (0.9% sodium chloride solution) and phosphate buffer solution (PBS) were used as 
solubility mediums since both are commonly used buffers in solubility studies and possess a neutral pH 
and desirable osmolarity. Based on TAF’s ionizable features and the hydrophilicity of TFV, high solubility 
in these buffers was expected.   
According to the pKa calculated by ChemAxon®, the pKa of TAF is 5.12 and 11.36 in its acidic 
and basic form, respectively. At neutral pH, TAF is both negatively and positively charged, with a net 
charge of zero. The compound in its non-ionized form always has a minimal solubility, whereas the 
charge on the compound increases its solubility. The charge on TAF is dependent on varying pH, and 
therefore affects solubility. As TAF is an ionizable compound, its solubility was predicted to be impacted 
by ionic strength as well.  
 TAF solubility in different buffers is indicated below (Table 3). TAF solubility decreased linearly 
with increasing pH (4-8) (Figure 6) and increasing ionic strength (150-1500 mosm/kg). (Figure 7) 
 
 
Table 3 Solubility of TAF in different media 
 
 
 
 
TAF was well suspended in media, rotated for 24h, centrifuged and then filtered by 0.22μm filters. The 
data represents the mean ± SD (n=3) of triplicates determinations. 
 
 
Solubility Medium Equilibrium solubility (mg/ml) 
Water 7.61 ± 0.42 
1XPBS 5.06 ± 0.11 
0.9% Saline 7.95 ± 0.70 
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Figure 6 Solubility of TAF at various pH. 
UPS citrate buffer (pH=4 and 5) and phosphate buffer (pH=6, 7 and 8) were used to control pH. TAF was 
well suspended in media, rotated for 24h, centrifuged and filtered by 0.22μm filters. The data represents 
the average of each vial of triplicates determinations (n=1). 
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Figure 7 Solubility of TAF at various ionic strength 
TAF was suspended in PBS buffer with various osmolality (150-1500mosm/kg), rotated for 24h, 
centrifuged and filtered by 0.22μm filters. The samples were analyzed using HPLC. The data represents 
the average of each vial of triplicates determinations (n=1). 
2.3.3 Hydrolysis  
Hydrolysis is one of the most common degradative chemical reactions over a wide range of pH. 
Hydrolysis peaks were observed on the HPLC chromatogram and did not interfere with the TAF main 
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peak at around tR=1.05min (Figure 8). Hydrolysis of TAF at various pH was expected at room 
temperature, due to its labile carboxyl ester bond.  
The rate of TAF hydrolysis increased with decreasing pH with statistical significant differences 
between each condition (p<0.05) (Figure 9). Using pH=2 forced degradations as an example, the 
hydrolytic degradant peak area was positively correlated with decreasing TAF peak area over time (Figure 
10). The calculated half-life of TAF forced by pH=2 buffer was 22h (R square was 0.99 and equation was 
shown in Figure 9). In 0.1M HCl, the TAF peak was not detected after 24h, suggesting the concentration 
is less than 0.17µg/ml. The TAF peak could not be detected once 0.1M NaOH was added. The figure 
below showed consistent hydrolysis peaks increased over time with TAF peaks decreased in pH=2 buffer 
(Figure 8).  
 
 
Figure 8 Overlay of chromatograms of hydrolytic stability test in pH=2 buffer.  
Hydrolysis peaks increased over time with TAF peaks decreasing. 
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Figure 9 Hydrolysis in USP buffers (pH=2, pH=4) and 0.1M HCl 
TAF stock solution prepared in 100% acetonitrile (7mg/mL) were diluted by hydrochloric buffer (pH=2) 
and citrate buffer (pH=4) to 70μg/mL and stored at room temperature. Drug content was measured on 
HPLC at predetermined time points for up to 24h. Data is reported as mean ± SD, n=3. 
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Figure 10 Linear correlation of hydrolysis peak area with time (h) (left) and TAF peak area at pre-
determined time points subtracted by TAF peak area at 0h (mAU·min) (right). 
TAF stock solution prepared in 100% acetonitrile were diluted by hydrochloric buffer (pH=2). TAF 
hydrolysis peak was measured on HPLC at predetermined time points for up to 24h. The peak areas 
(mAU·min) were plotted against time (h) and hydrolytic degradant peak areas (mAU·min). The equation 
of linear regression in Figure 10 (left) is Y=0.118*X+0.086, and the R square is 0.995. The equation of 
linear regression in Figure 10 (right) is Y=0.009*X-0.053, and the R square is 0.998 (n=3). 
 
 
2.3.4 Thermal and Photolytic Stability 
 
The calculated half-life of TAF thermal degradation was 13 days under 60°C based on linear 
regression (R square and equation were shown in Figure 11). A 10% loss was investigated at 65h under 
60°C (Figure 11).  
In photolytic studies, TAF was prepared directly in water at 1mg/mL and diluted as 120μg/mL. 
Only 1% loss was observed at 72h.  
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Figure 11 Thermal stability study at 40°C and 60°C  
TAF stock solution prepared in 100% acetonitrile were diluted to 70 μg/mL with water and stored in 
amber glass vials, sealed and put in 40°C and 60°C water baths and monitored for 72h. 100 μL samples 
were taken on predetermined time points and drug contents were measured on HPLC. The equation of 
linear regression at 60°C is Y = -0.164*X + 101, and the R square is 0.987. The average of each vial was 
reported with triplicates determinations (n=1).  
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2.3.5 Oxidation 
Oxidation is a common chemical process that entails the loss of electrons and the transfer of 
electrons between reactive groups. Amines and phenols present in TAF’s structure are susceptible to 
electron transfer oxidation to yield N-oxides, hydroxylamine, and sulfones [63, 64]. Benzylic carbons and 
tertiary carbons, present in the TAF benzene ring and carbon chain, contain labile hydrogen and are 
susceptible to oxidation, forming hydro peroxides or ketones [64, 65]. Therefore, it was expected that 
TAF could be oxidized under hydrogen peroxide at room temperature.  
TAF diluents forced by 0.03% H2O2 had no significantly statistical drug loss within 3 days 
(p=0.06). 99.85% drug recovery was obtained at 24h forced by 0.03% H2O2, as opposed to 77.68% drug 
recovery forced by 3% H2O2 (Figure 12). No oxidative degradant peak was observed on HPLC 
chromatographs 
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Figure 12 Oxidation study by 0.03% and 3% H2O2 
TAF stock solution were diluted with 30% H2O2 and 3% H2O2 solution by water and stored at room 
temperature for 24h of 3% H2O2 solution and 72h of 0.03% H2O2 solution. Drug content were measure on 
HPLC at predetermined time points Y-axis is drug content at predetermined time points normalized to 
drug content at time zero (100%). The equation of linear regression at 3% H2O2 is Y= -0.961*X+101 and 
R square is 0.992. Drug content at 0.03% H2O2 had no statistically significant decrease within 72h 
(p=0.06). Data is reported as mean ± SD, n=3. 
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2.3.6 Preservative Compatibility 
The average recovery without parabens was 98.8%±0.6% and after addition of parabens was 
98%±0.53%. There is no statistical difference (p=0.097) before and after addition of sodium parabens 
concerning drug content recovery ratio (normalized to actual weighed amount divided by volume). Table 
4 below shows the concentrations of each independent TAF enema during preparation. All enemas 
followed the same preparation procedure (see 2.2.6)  
Table 4 Preservative compatibility. 
 
  
Theoretical 
Concentration 
Actual 
Concentration 
without 
Parabens 
Actual 
Concentration 
after Addition of 
Parabens 
Recovery 
without 
Parabens 
Recovery after 
Addition of 
Parabens 
(mg/ml) (mg/ml) (mg/ml)  (%) (%) 
1 1.8 1.77±0.020 1.77±0.006 98.2 98 
2 1.81 1.79±0.005 1.76±0.009 99 97.4 
3 1.76 1.75±0.006 1.74±0.020 99.2 98.6 
 
TAF enemas were first prepared according to preparation procedure without preservative, analyzed by 
HPLC and then preservative was added followed by drug content analysis. Data is reported as mean ± 
SD, n=3. The recovery ratio is the mean of actual concentrations divided by the mean of theoretical 
concentrations. The results of three independent experiments are reported separately.  
2.3.7 One-Week Stability 
Short-term stability testing of drug product formulation was carried out in three conditions: long 
(25°C ± 2°C/60% RH ± 5% RH), intermediate (30°C ± 2°C/65% RH ± 5% RH), and accelerated (40°C ± 
2°C/75% RH ± 5% RH), according to the International Conference on Harmonization (ICH) Q1A (R2). 
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The specification of drug content is within 10%, pH within 6-8 and osmolality within ±5 (Isotonic: 
290mosm/kg and hypotonic: 150mosm/kg).  
Results show that higher temperatures forced faster degradation. For isotonic and hypotonic TAF 
enemas conducted at 40°C (Figure 13), 30°C (Figure 14), 25°C (Figure 15), the chemical degradations 
forced by thermal conditions followed zero-order kinetics at 30°C and 25°C (R square were all greater 
than 0.98). The percent of drug remaining was plotted as a function of time. The calculated half-life was 
based on linear regression equations (equations shown in Figure 14 and Figure 15).  The calculated half-
life for isotonic enemas was 17 days and 27 days at 30°C and 25°C, respectively. For hypotonic TAF 
enemas, the half-life was 19 days and 33 days, respectively. When comparing isotonic and hypotonic TAF 
enemas, there was no obvious difference in degradation rate. Isotonic TAF enemas at 25°C had 10% loss 
of drug content at day 5 in comparison with hypotonic TAF enemas at day 7. For pH and osmolality, they 
were both within the specification range within 7 days. A slight decrease in pH was observed over 7 days 
(Table 5 and Table 6). Osmolality did not change significantly over time. (Table 7 and Table 8) 
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Figure 13 Drug recovery of isotonic and hypotonic TAF enemas in 40°C/75% RH environmental 
chamber 
Isotonic and hypotonic TAF enemas in 30mL capped glass bottle were stored in 40°C/75%RH 
environmental chamber. 1mL aliquots were taken each time, diluted by 25% acetonitrile and drug 
contents were analyzed by HPLC at predetermined time points. The equation of the linear regression of 
isotonic TAF enema is Y= -4.082X+98.22, R square is 0.942 and the equation of the linear regression of 
hypotonic TAF enema is Y= -4.295*X+97.5, R square is 0,980. The data represents the average of each 
vial of triplicates determinations (n=1). 
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Figure 14 Drug recovery of isotonic and hypotonic TAF enemas in 30°C/65% RH environmental 
chamber 
Isotonic and hypotonic TAF enemas in 30mL capped glass bottle were stored in 30°C/65%RH 
environmental chamber. 1mL aliquots were taken at each time point, diluted by 25% acetonitrile and drug 
content was analyzed by HPLC at predetermined time points. The equation of the linear regression of 
isotonic TAF enema is Y= -4.082X+98.22, R square is 0.942 and the equation of the linear regression of 
hypotonic TAF enema is Y= -4.295*X+97.5, R square is 0,980. The data represents the average of each 
vial of triplicates determinations (n=1). 
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Figure 15 Drug recovery of isotonic and hypotonic TAF enemas in 25°C/60% RH environmental 
chamber 
Isotonic and hypotonic TAF enemas in 30mL capped glass bottle were stored in 25°C/60%RH 
environmental chamber. 1mL aliquots were taken at each time point, diluted by 25% acetonitrile and drug 
content was analyzed by HPLC at predetermined time points. The equation of the linear regression of 
isotonic TAF enema is Y= -4.082X+98.22, R square is 0.942 and the equation of the linear regression of 
hypotonic TAF enema is Y= -4.295*X+97.5, R square is 0,980. The data represents the average of each 
vial of triplicates determinations (n=1). 
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Table 5 pH of hypotonic TAF enema 
pH Time0 Day2 Day3 Day5 Day7 
40°C 6.84 6.81 6.8 6.67 6.59 
30°C 6.84 6.89 6.85 6.74 6.78 
25°C 6.84 6.88 6.89 6.83 6.84 
 
Hypotonic TAF enemas were stored in environmental chambers with temperature of 40°C, 30°C, 25°C 
and pH was tested at predetermined time points, n=1. 
 
 
 
Table 6 pH of isotonic TAF enema 
pH Time0 Day2 Day3 Day5 Day7 
40°C 6.76 6.79 6.69 6.59 6.55 
30°C 6.76 6.87 6.81 6.75 6.68 
25°C 6.76 6.92 6.89 6.84 6.86 
 
Isotonic TAF enemas were stored in environmental chambers with temperature of 40°C, 30°C, 25°C and 
pH was tested at predetermined time points, respectively, n=1. 
 
 
 
Table 7 Osmolality of hypotonic TAF enema 
Osmolality 
(mosm/kg) 
Time0 Day1 Day2 Day3 Day5 Day7 
40°C 155 154 157 156 161 159 
30°C 155 152 157 155 156 158 
25°C 155 155 155 155 156 156 
 
Hypotonic TAF enema were stored in environmental chambers with temperature of 40°C, 30°C, 25°C and 
osmolality was tested at predetermined time points, respectively, n=1. 
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Table 8 Osmolality of isotonic TAF enema 
Osmolality 
(mosm/kg) Time0 Day1 Day2 Day3 Day5 Day7 
 40°C 288 288 290 290 294 294 
30°C 288 286 288 286 287 288 
25°C 288 287 291 286 290 294 
 
Isotonic TAF enemas were stored in environmental chambers with temperature of 40°C, 30°C, 25°C and 
osmolality was tested at predetermined time points, respectively, n=1. 
2.3.8 The Relationship of Temperature and Degradation Rate  
For thermally accelerated temperature, the most commonly used kinetic model used to interpret 
the effect of temperature on reaction rate is the Arrhenius equation [66, 67]. The Equation 1 is shown 
below. 
 
 
k = reaction rate constant 
A = Arrhenius factor (y-intercept constant) 
Ea = the energy of activation for the reaction, cal/mole (1000 cal = 1 kcal)   
R = the ideal gas constant, 8.3144598 J mol−1 K−1 
T = the absolute temperature (degrees Kelvin)  
The degradation rate at each temperature is firstly estimated,  then using proper weighting, the 
logarithm of degradation rate is plotted as a function of reciprcal absolute temperature [67]. For many 
reactions, This linear relationship can be obtained between the inverse of temperature (in degrees Kelvin) 
and the natural log (ln) of the measured rate constant (k), determined by the Arrhenius equation [66]. This 
k = A exp (-Ea/RT) 
Equation 1 Arrhenius equation 
 44  
linear relationship means that the effect of the temperature on the reaction rate is maintained which 
indicates the reaction mechanism has no change over the range of temperature [66]. In our study, linear 
relationships were obtained between time and drug content at 25°C, 30°C and 40°C which indicated that 
degradation were all zero-order. The Equation 2 is the linear form of Equation 1 for graphical 
presentation.  
  
 
Based on the content of linear regression equations of TAF enemas under three conditions 
(25°C/60% RH, 30°C /65% RH, 40°C/75% RH), the relationship between temperature and degradation 
rate of isotonic and hypotonic TAF enemas can be defined by the equations are k=984609×exp-10.26/RT and 
k=23207824×exp12.29/RT respectively. The unit of Ea is Kcal/mole.  
Then we can use the model to calculate the shelf-life at any other combination of temperatures 
and storage intervals at each temperature [67]. For zero-order reaction, α(t)=At×exp–Ea/RT can be used to 
calculate the fraction degraded at any time t and any temperature T [67].  
The limitation of this model is when monitoring the generation of a primary degradation product, 
if a secondary degradation reaction happening during the reaction can introduce error to the calculation of 
the primary rate constant, meaning the reaction rate will not be a constant under this condition [66]. 
 
  DISCUSSON AND CONCLUSION 
 
The overall goal of the preformulation studies was to evaluate the physicochemical properties of 
the API and its stability profile under various conditions. In the current work, preformulation studies have 
ln k = -Ea/RT + ln A 
Equation 2 y=mx+b format of Arrhenius 
equation 
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shown that TAF is a promising microbicide candidate. This API is slightly soluble in water and other 
commonly used media at various pH. There was no statistical difference between solubility of TAF in 
0.9% saline and water and they were both significantly higher than solubility in PBS from one-way 
ANOVA Bonferroni post-hoc test (p=0.0018 and p=0.009 for comparisons of water and 0.9% saline with 
PBS, respectively). All solubility results indicated that TAF is able to reach the target concentration of 
1.76mg/ml without aide of solubilizing excipients. This solubility is desirable for incorporation into many 
dosage forms such as aqueous gels, suppositories, and enemas. The reason why PBS, 0.9% saline and 
water were chosen as the solubility media was that it was desired to have the enema formulated in a 
water-based medium. Secondly, 0.9% saline and PBS have different ionic compositions that might affect 
solubility. In addition, the pH difference between these three media would give us hints on whether pH 
would affect the solubility of TAF. As enemas are largely composed of water and are less viscous 
resulting in their potential enhanced coverage of the large surface area of colorectal epithelium when 
applied, high solubility of TAF can allow drug delivery into the colorectal lumen. Delivery to this location 
can provide sufficient dosing and a long dose regimen. 
However, the task of formulating TAF into an enema product remains challenging due to its 
hydrolysis at acidic pH conditions or at temperatures of 25°C and higher. In order to progress TAF 
enemas into animal studies and prolong the shelf life, the stability of TAF enemas must be enhanced.  
In the solubility studies conducted, the solubility of TAF decreased with increased pH and ionic 
strength. Therefore, incorporating higher concentrations of TAF into enemas within pH 6-8 might be 
problematic.  
In the hydrolysis preformulation study, TAF hydrolysis rate increased with decreasing pH 
(p<0.0001 for three groups comparison), which was consistent with the knowledge that extreme pH will 
promote hydrolysis. Hydrolysis was found to contribute to the overall loss in drug content, as a linear 
relationship was determined after plotting hydrolysis peak area with TAF peak area decrease at 
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corresponding time points. Comparing hydrolysis tests in the preformulation studies with pH=6-8 in the 
stability tests at 25°C, TAF in pH=4 buffer was predicted to have 90% of claimed drug label at 5 days, as 
opposed to approximately 6 days with pH close to 7.  
In the thermal preformulation study, two storage conditions, 40°C and 60°C, were chosen and 
utilized as accelerated temperatures to facilitate the degradation rate. Data showed that both 40°C and 
60°C promoted degradation. The data obtained at 40°C at 72h showed a large variation so the degradation 
rate at 40°C could not be calculated. It is commonly agreed that higher temperature accelerates 
degradation based on Arrhenius equation. More experiments are needed to confirm the degradation rate at 
40°C and the comparisons between temperatures can be made. In the stability test, three conditions 
(25°C/60% RH, 30°C /65% RH, 40°C /75% RH) were chosen to assess the shelf life of TAF enemas. The 
calculated shelf life of 90% claimed drug label is 5 days, 6 days and a half for isotonic TAF enemas and 
hypotonic TAF enemas within 95% confidence interval, respectively. The calculated shelf lives of the 
products were both the lower confidence limit of the estimated time. In terms of thermal stability, isotonic 
or hypotonic enemas were similarly affected by varying temperatures.  
During the process of formulation, storage, handling and application in vivo, many sources of 
oxidation exist, including the use of organic solvents and excipients during formulations and H2O2 
produced by lactobacillus in the female reproductive tract. Studies have showed that H2O2-producing 
vaginal lactobacillus species in the rectum may contribute to the maintenance of vaginal microflora and 
serve as a reservoir for vaginal colonization by lactobacilli, especially after a disturbance of the ecology 
that follows douching or sexual intercourse [68]. In the current study, 3% hydrogen peroxide was applied 
to test TAF oxidative stability, revealing a 10% loss by day 11th. However, lactobacillus in vivo secrete 
only 0.03% H2O2, and. no statistically significant (p=0.063) drug loss was observed in this study under 
0.03% H2O2 conditions after 3 days. It is unlikely that the microbicide product in the rectum will 
experience a higher H2O2 percentage, and therefore, stability in the rectal tract can be ensured. Although 
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rectal exposure to H2O2 should not affect TAF stability, environmental H2O2 may still cause degradation. 
Antioxidants are commonly used additives in food and drug fields may increase oxidation stability if 
incorporated into liquid based formulations. Antioxidant vitamins, for example, vitamin C (ascorbic acid) 
which is a water-soluble free radical scavenger or ethylenediaminetetraacetic acid (EDTA) might be able 
to incorporate in liquid based formulations. Further investigation of suitable antioxidants is needed to 
stabilize TAF enemas against oxidative environment.  
As discussed above, hydrolysis is a major issue affecting stability of TAF enemas. Hydrolytic 
degradants might be ionizable and affect pH and osmolality. The pH and osmolality were monitored 
during the stability test. Strategies to prevent hydrolysis of drug-like compounds that have been employed 
include intercalation into liposomes, solubilization in micro-emulsions, entrapment in microspheres, and 
formation of inclusion complexes [69]. It has been reported that encapsulation of curcumin in cationic 
micelles suppresses alkaline hydrolysis by cationic surfactants cetyl trimethylammonium bromide 
(CTAB) and dodecyl trimethylammonium bromide (DTAB) [70]. When in alkaline solution, cationic 
surfactants entrapped curcumin and prevented contact with water, thus largely suppressing its hydrolysis 
in alkaline solution [70]. Carboxyl ester, organophosphate and phosphoamide groups present in TAF 
structure are subject to acidic and alkaline hydrolysis [40]. Once hydrolyzed, negatively charged species 
form. The surfactants CTAB and DTAB may be suitable for incorporation into TAF enemas to form 
micelles and suppress hydrolysis of TAF. Further investigation is needed to explore the compatibility, 
effects, and toxicity of these chosen and whether addition prevents hydrolysis.  
Sodium parabens are freely dissolvable in water and have no impact on TAF drug content. 
Therefore, it can be concluded that sodium methylparaben and propylparaben are compatible with TAF in 
enemas. However, the antibacterial effects of these two parabens in TAF enemas remain unknown and 
require further exploration.  
 48  
In conclusion, the preformulation evaluation preformed in this chapter affirmed that TAF is a 
promising drug candidate for the development of rectal water-based microbicides. The studies in this 
chapter also reveal that hydrolysis under pH and thermal stress conditions represent major challenges for 
the formulation development of TAF enemas. Additionally, oxidation may be an issue during storage, thus 
it is important that packaging options which can protect from oxidation be explored. The use of 
pharmaceutical strategies that can encapsulate and protect TAF as well as the utilization of protective 
pharmaceutical inactive ingredients must be studied further to improve TAF stability against stress-
induced hydrolysis.  
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3.0  DESIGNING CMX157 ENEMAS FOR HIV PREVENTION 
 
 THE RATIONAL OF DESIGNING CMX157 ENEMAS 
 
Since CMX157 has shown promise as a potent TFV prodrug, incorporation into rectal enemas 
was investigated. After initial solubility studies revealed CMX157 possesses 3mg/ml solubility in 1X 
PBS, a commonly used buffer that is safe for rectal use, preformulation development for CMX157 
enemas began. The target concentration of CMX157 in a water-based enema is 1.76mg/ml based on TFV 
enemas. As opposed to TAF, CMX157 has organophosphate (esters of phosphoric acid) groups that can be 
hydrolyzed only under extreme conditions[40]. Likewise, ether is considered relatively unreactive and 
often used to protect alcohol from oxidation[63]. However, ether can be hydrolyzed by hydrogen 
bromide, a commonly used acid slightly stronger than HCl. Reactive 1º- alcohol group is subject to 
oxidation[65]. In conclusion, CMX157 was considered for incorporation into rectal enemas due to its 
anti-retroviral activities, solubility in PBS, and low chance of hydrolysis under normal conditions.  
 
 MATERIALS & METHODS 
3.2.1 HPLC Development 
CMX157 was analyzed on a BDS Hypersil (Thermo Fisher Scientific, Waltham, MA) C8 column 
(3μm, 150 ×4.6 mm) using the Waters HPLC system connected to a diode array detector (Waters 2996 
photodiode Array). A gradient elution was utilized by mobile phase A (25mM phosphate buffer and 5mM 
t-butyl ammoniumbromide, pH=3) and B (100% Methanol) for 24 min at a flow rate of 1mL/min at 
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ambient temperature in auto-sampler. Sample injection volume was 10μL. Table 9 shows the gradient 
elution.  
Table 9 CMX157 gradient elution compositions 
 
 
 
 
 
3.2.2 CMX157 Enemas Formulas and Preparations 
Table 10 shows formulas for isotonic and hypotonic CMX157 enemas in PBS buffered systems. 
1XPBS and 0.5XPBS were diluted from purchased 10XPBS. After PBS preparation, CMX157 was added 
and stirred for 5mins. The resulting solution was sonicated until all components were dissolved. After 
sonication, pH and osmolality were immediately recorded. 
 
Table 10 Preliminary formulations of CMX157 isotonic and hypotonic enemas 
 
Component 
(Isotonic) 
Amount Per Batch 
Component  
(Hypotonic) 
Amount Per Batch 
1XPBS 20mL 0.5XPBS 20mL 
CMX157 35.2mg CMX157 35.2mg 
 
 
Time (min) Mobile phase A Mobile phase B 
Initial 50% 50% 
2 50% 50% 
10 10% 90% 
20 10% 90% 
22 50% 50% 
24 50% 50% 
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 RESULTS 
3.3.1 HPLC Method 
An HPLC analytical method was developed and validated. The retention time of CMX157 was 
observed at 17.9 minutes. The LOD was estimated to be 5μg/mL, and the LOQ was 0.17μg/mL. A linear 
standard curve was obtained over a range of 0.5~120μg/mL. No CMX157 degradants were detected 
during the analysis. The perfect overlay among the 10 CMX157 chromatograms represents the 
repeatability of samples at the low QC level (5ug/mL) (Figure 16). This developed HPLC method was 
applied to quantify solubility of CMX157 in different solvents and drug concentrations in samples 
collected throughout the stability studies. The R square of the validation curves were all greater than 0.99. 
The CV reported as RSD were shown in Table 11. 
  
Figure 16 HPLC chromatograms overlay of 10 injections of low QC level of CMX157 (5μg/mL) 
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10 injections of each QC level were made on each day of three days. RSD was 0.981% for injections 
shown above. TAF peaks were consistent on each day. 
 
Table 11 Precision results of CMX157 validation for three days 
 
3.3.2 CMX157 Enemas Characterizations 
 
The pH and osmolality of CMX157 enemas are shown below. 
 Table 12 pH of CMX157 enema 
 
 
 
Data is reported as Mean ± SD, n=3 
Table 13 Osmolality of CMX157 enema 
 
 
Data is reported as Mean ± SD, n=3 
RSD 
(%) 
Low  
Conc. 
Middle 
 Conc. 
High  
Conc. 
Precision 7.25% 4.43% 25.4% 
  pH 
1XPBS CMX157 enemas 6.83 ± 0.01 
0.5XPBS CMX157 enemas 6.58 ± 0.02 
  
Osmolarity 
(mosm/kg) 
1XPBS CMX157 enemas 306 ± 2 
0.5XPBS CMX157 enemas 142 ± 2 
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4.0  MAJOR SIGNIFICANCE, LIMITATIONS AND FUTURE DIRECTIONS 
A safe, effective HIV PrEP strategy with high levels of adherence is urgently needed to protect 
men and women at highest risk of HIV infection from anal sex, where risk of transmission far exceeds 
that of penile-vaginal sex [71]. The Development of a Rectal Enema As Microbicide (DREAM) program 
addresses this critical need to develop a highly effective, safe, and behaviorally-congruent alternative for 
the prevention of rectal HIV infection [71]. The overall goal of the program is to develop a single dose 
pericoital enema to deliver a TFV prodrug capable of providing one week of HIV protection[71]. This 
strategy builds upon proven high levels of efficacy of TFV-based PrEP in adherent persons and directly 
targets adherence as the greatest weakness of PrEP regimens [71]. Given the common practice of rectal 
douching with an enema prior to receptive anal sex, using an enema as HIV prevention would require 
little behavioral change [71]. TAF and CMX157 are potent prodrugs of TFV that have better cellular 
uptake than TFV, which increases concentration of TFV in PBMCs and are beneficial in reducing dosage 
and prolonging dosing regimens [26]. As little information is available in the literature regarding the 
physiochemical characteristics of these two prodrugs, it was necessary to develop crucial preformulation 
studies to better understand development of microbicide formulations.  
TAF is a promising microbicide candidate for incorporation into enemas as it has sufficient 
solubility in water and other commonly used solubility media such as water, saline and PBS. In this study, 
TAF aqueous solubility is sufficient to achieve the 1.76mg/ml target concentration without aide of 
solubilizers. Our clinical collaborator set this target concentration for the TFV enema. However, TAF was 
prone to degradation under stressed conditions, an acidic environment (pH4), and high temperature 
environment (25°C). These characteristics have been anticipated from the chemical structure of TAF. 
TAF has a carboxyl ester bond labile to hydrolysis. Amines and phenols present in TAF’s structure are 
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susceptible to electron transfer oxidation to yield N-oxides, hydroxylamine, and sulfones [63, 64]. 
Benzylic carbons and tertiary carbons, present in TAF benzene ring and carbon chain, which contain 
labile hydrogen, are also susceptible to oxidation to form hydro peroxides or ketone s[64, 65]. There are 
many strategies available to stabilize drug products against various environments. For oxidative 
environments, antioxidant reagents such as antioxidant vitamins or EDTA were proposed to solve 
instability in oxidative environment. For stressed acidic and thermal conditions, micelles made by 
cationic surfactants, such as CTAB and DTAB, were proposed to suppress hydrolysis [70]. More research 
is needed for stabilization of TAF in water-based media, in order to progress TAF enemas to animal 
studies.  
Little data is obtained in this thesis work about the chemical characteristics of CMX157. As 
predicted from the chemical structure of CMX157, it may have less solubility compared with TAF due to 
its nineteen carbon chain and be subject to oxidation attributed to that 1º-alcohol group that links to 
organophosphate is a reactive group, which is subject to oxidation [65]. The HPLC method developed for 
CMX157 needs further optimization. Preliminary solubility data showed that CMX157 was soluble in 
1XPBS (3mg/ml). Preliminary CMX157 formulations in PBS buffered system have reached the desired 
pH and osmolality range without further adjustments. Drug content evaluation, stability testing, and some 
necessary pre-formulation work are needed to optimize this formulation. A once-weekly dosing regimen 
of CMX157 was recommended because PBMC levels of TFV-DP remained detectable for six days after 
the single 400 mg dose due to high intracellular uptake of CMX157 [26].  Solubilizing CMX157 might be 
needed to achieve this one-week dosing regimen, which should enhance patient compliance. Refrigerator 
storage has been recommended for CMX157. We observed degradation peaks when temperature was not 
well controlled. Therefore, extra caution regarding temperature control should be used when developing 
analytical tools and determining storage conditions for CMX157.  
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The goal of the work written in this thesis was to develop a rectally applied, HIV-preventive, 
TFV prodrug enema. Dosing recommendations for future work with TAF and CMX157 for non-human 
primate and human studies based on both multi-compartment pharmacokinetics and antiretroviral 
pharmacodynamics is not currently available [71]. Formulations developed in this study sought to 
promote colonic absorption without compromising epithelial integrity in the colorectum by osmolality 
and pH control [32, 50]. The pH range (pH 6-8) of TFV prodrug enemas was selected based on studies 
conducted by Lin Wang (Magee Women’s Research Institute, Pittsburgh, PA) and World Health 
Organization (WHO) recommendations [32, 39]. The aim was to relieve potential discomfort resulting 
from extreme pH. However, due to the varying physiochemical characteristics between different 
compounds, the pH range should be chosen based on achieving stable formulations of the specific drug 
substance.  
In conclusion, these studies demonstrated the feasibility for formulation of 1.76 mg/ml of TAF in 
an enema dosage form. However, further work to enhance stability of TAF in this aqueous based enema 
dosage form is needed to prevent against oxidative, hydrolytic, and thermal conditions.  
There are several limitations in the presented studies that may be addressed in future work. For 
solubility studies, solubility results obtained in this work require further investigation. The current 
developed HPLC method for TAF is not fully stability-indicating as the oxidative degradant peak could 
not be detected. This might result in decreased solubility results if there was any oxidation occurring 
during the solubility study. The current HPLC method for TAF should be adjusted to obtain more 
information on TAF degradants. In the hydrolysis test by different buffers with varying pH, acidic and 
basic buffers were used, but neutral buffers were not tested. In the formulations we developed in this 
project, pH 6-8 was selected as the target range, with pH=6 being more acidic and pH=8 being more 
basic. According to the current pH range (pH=1,2,4 and 11) used in the hydrolysis test of TAF, little 
information is obtained that predicts whether TAF is stable in this range. Hydrolysis studies of TAF at 
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pH=6 to pH=8 buffers are needed to justify the hypothesized pH range, with respect to formulation 
stability. In TAF hydrolysis and thermal studies, the UV detector detected hydrolysis peaks eluted at 
consistent time points that all had the same absorption, suggesting that one degradant could be detected 
by the developed HPLC method. However, the identity of this degradant is unclear, which should be 
explored to rule out any toxic degradants.  
In this thesis work, not only has the chemical characteristics of TAF been explored by 
preformulation studies, but the formulations of TAF and CMX157 enema were also developed. These 
studies represent the first time that TAF and CMX157, as TFV prodrugs, have been developed as an 
enema product intended to be used as a rectal microbicide. Meanwhile, the preformulation studies on 
solubility and stability of TAF under various conditions provide insight into the possibility of developing 
other liquid based formulations. Enemas, incorporating TFV prodrugs, could offer a means of protection 
for people who engage in AI. The understandings and findings in this thesis work serve as a basis for 
future development of rectal microbicide enema products, as well as provide important information 
required for formulation of TFV prodrugs. 
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6.0  APPENDIX A 
ABBREVIATION 
1. Men who have sex with men—MSM 
2. Anal intercourse—AI 
3. Dendritic cells—DCs 
4. Sexually Transmitted Disease—STDs 
5. Centers for Disease Control and Prevention—CDC 
6. Pre-exposure prophylaxis—PrEP 
7. Tenofovir disoproxil fumarate—TDF 
8. Emtricitabine—FTC 
9. Antiretrovirals—ARVs 
10. Nucleotide/nucleoside reverse transcriptase inhibitors—NRTIs 
11. Reverse transcriptase—RT 
12. Tenofovir—TFV 
13. Reduced glycerin TFV gel—RG-TFV gel 
14. Tenofovir alafenamide fumarate—TAF 
15. Tenofovir-diphosphate—TFV-DP 
16. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide—D/C/F/TAF 
17. Darunavir/cobicistat/emtricitabine/tenofovir disoproxil fumarate—D/C/F/TDF 
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18. Hexadecyloxypropyl-Tenofovir—CMX157 
19. hexadecyloxypropyl—HDP 
20. Unprotected receptive anal intercourse—URAI 
21. Simulated colon solution—SCS 
22. Active pharmaceutical ingredients—APIs 
23. tris buffered saline—TBS 
24. High performance liquid chromatography—HPLC 
25. Phosphate buffer solution—PBS 
26. Hydrochloric acid—HCl 
27. Sodium hydroxide—NaOH 
28. Hydrogen peroxide—H2O2 
29. U.S. Food and Drug Administration—FDA 
30. The International Council for Harmonisation—ICH 
31. Limit of detection—LOD 
32. Limit of quantification—LOQ 
33. Ethylenediaminetetraacetic acid—EDTA 
34. High Performance Liquid Chromatography—HPLC 
35. Quality control-QC 
36. Coefficient of variation-CV 
37. Relative standard deviation-RSD 
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